The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis

Journal of Physiology and Pharmacology

Volumn 62, Issue 4, 2011, Pages 469-472

  Raithel, Martin ^a   Zopf, Y ^a   Kimpel, S ^a   Naegel, A ^a   Molderings, G J ^c   Buchwald, F ^b   Schultis, H W ^b   Kressel, J ^a   Hahn, E G ^a   Konturek, P ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Medical Laboratory   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Thueringen Klinik Saalfeld   (Germany)

Author keywords

Biomarker; Cysteinyl leukotrienes; Leukotriene B4; Leukotrienes excretion; Mastocytosis; Methylhistamine

Indexed keywords

HISTAMINE DERIVATIVE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIARRHEA; DIGESTIVE SYSTEM ULCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL PAIN; HUMAN; MALE; SKIN MANIFESTATION; SYSTEMIC MASTOCYTOSIS; URINALYSIS; URINARY EXCRETION; VOLUNTEER;

BIOLOGICAL MARKERS; CYSTEINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOTRIENE B4; LEUKOTRIENES; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED;

EID: 82155192148     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bedeir A, Jukic DM, Wang L, Mullady DK, Regueiro M, Krasinskas AM. Systemic mastocytosis mimicking inflammatory bowel disease: a case report and discussion of gastrointestinal pathology in systemic mastocytosis. Am J Surg Pathol 2006; 30: 1478-1482.
2. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 2011; 4: 10.
3. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalf DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91: 612-624.
4. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
5. Schaefer D, Baenkler HW. Functional eicosanoid test and typing (FET) of peripheral blood cells in eicosanoids related diseases. J Physiol Pharmacol 2005; 56(Suppl 5): 103-118.
6. Keyzer JJ, de Monchi JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983; 309: 1603-1605.
7. Raithel M, Hahn EG, Baenkler HW. Klinik und Diagnostik von Nahrungsmittelallergien: gastrointestinal vermittelten Allergien Grad I bis IV. Deutsch Aerztebl 2002; 99: A780/B641/C599.
8. Cysteinyl-Leukotriene ELISA. Instructions for use. IBL Immuno-Biological Laboratories, Hamburg, Germany, 2004.
9. Westcott JY, Johnston K, Batt RA, Wenzel SE, Voelkel NF. Measurement of peptidoleukotrienes in biological fluids. Am J Physiol 1990; 232: 2640-2648.
10. Winterkamp S, Weidenhiller M, Otte P, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 3071-3077.
11. Winterkamp S, Weidenhiller M, Wilken V, et al. Standardised evaluation of urinary excretion of N-telemethylhistamine in different periods of age in a healthy population. Infl Res 2003; 52: S57-S58.
12. Stanke-Labesque F, Pofelski J, Moreau-Gaudry A, Bessard G, Bonaz B. Urinary leukotriene E4 excretion: A biomarker of inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 769-774.
13. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2010; 92: 73-76.
14. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis: Hematol Oncol Clin North Am 2000; 14: 579-623.
15. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350: 735-736.
16. Wisniewska-Jarosinska M, Chojnacki J, Konturek S, Brzozowski T, Smigielski J, Chojnacki C. Evaluation of urinary 6-hydroxymelatonin sulphate excretion in women at different age with irritable bowel syndrome. J Physiol Pharmacol 2010; 61: 295-300.
17. Castells M, Austen KF. Mastocytosis: mediator related signs and symptoms. Int Arch Allergy Immunol 2002; 127: 147-152.
18. Fee WH. Irritable bowel syndrome helped by montelukast. Chest 2002; 122: 1497.
19. Rodriguez T, Pfeffer M, Levy BD, Castells M. Lipid mediators in cutaneous and systemic mastocytosis and impact of 5-LO inhibition. (abstract). J Allergy Clin Immunol 2011; 127(Suppl 1): AB132.
20. Healy E, Newell L, Howrth P, Friedmann PS. Control of salicylate intolerance with fish oils. Br J Dermatology 2008; 159: 1368-1369.
21. Bryk D, Zapolska-Downar D, Malecki M, Hajdukiewicz K, Sitkiewicz D. Trans fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor-kB activation. J Physiol Pharmacol 2011; 62: 229-238.